Protocol Ledger

NCT06922045 · Phase III · ACTIVE NOT RECRUITING

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Interventional Phase III clinical trial protocol NCT06922045 sponsored by Jiangsu BioJeTay Biotechnology Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-26 Enrollment: 40 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06922045
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06922045
Protocol FieldVerified Registry Value
NCT IdentifierNCT06922045
Consolidated Lead SponsorJiangsu BioJeTay Biotechnology Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment40 participants (ACTUAL)
Registered Start Date2025-03-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI